about
Pathological evolution of hepatitis C virus-“Healthy carriers”Nucleotide sequence and tissue distribution of the human mitochondrial aspartate aminotransferase mRNAA Proof of Concept, Phase II Randomized European Trial, on the Efficacy of ALF-5755, a Novel Extracellular Matrix-Targeted Antioxidant in Patients with Acute Liver DiseasesGenome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.Intrahepatic hepatitis C virus RNA quantification in microdissected hepatocytes.Argentine tango: Another behavioral addiction?Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?Clinical management methods for out-patients with alcohol dependenceBrief report: genetics of alcoholic cirrhosis-GenomALC multinational studyChanges to hepatocyte ploidy and binuclearity profiles during human chronic viral hepatitis.Variation in AUDIT (Alcohol Use [correction of Used] Disorder Identification Test) scores within the first weeks of imprisonment.Investigation of Cognitive Improvement in Alcohol-Dependent Inpatients Using the Montreal Cognitive Assessment (MoCA) Score.Follow-Up of Alcohol Consumption After Liver Transplantation: Interest of an Addiction Team?A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients.Hepatocellular carcinoma in alcoholics.Interactions between alcohol and hepatitis viruses in the liver.Chronic alcohol intoxication decreases the serum level of hepatitis B surface antigen in transgenic mice.Impact of common risk factors of fibrosis progression in chronic hepatitis C.BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease.Alcohol and hepatitis C virus core protein additively increase lipid peroxidation and synergistically trigger hepatic cytokine expression in a transgenic mouse model.Reversibility of hepatitis C virus-related cirrhosis.Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C.Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa.Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C.ESBRA 1997 Award lecture: relationship between excessive alcohol drinking and viral infections.Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users.Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C.Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C.Hepatitis C virus RNA in serum of blood donors with or without elevated transaminase levels.HCV infection in alcoholics.Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group.IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes.Impact of medical recommendations on alcohol consumption in HCV positive patients.Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection.Impact of tobacco and alcohol consumption in patients registered on waiting list on early morbidity following liver transplantation.The prevalence of optic neuropathy in alcoholic patients--a pilot study.Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease.Management of hepatitis C virus infection in heavy drinkers.T-cell responses to hepatitis B splice-generated protein of hepatitis B virus and inflammatory cytokines/chemokines in chronic hepatitis B patients. ANRS study: HB EP 02 HBSP-FIBRO.Noninvasive in vivo liver fibrosis evaluation using supersonic shear imaging: a clinical study on 113 hepatitis C virus patients.
P50
Q27489097-842486FE-E4B5-42FA-B544-3365DAC426A1Q28292946-82A0CF7E-879B-4598-AD9D-7A514BAD75E5Q28550755-B49A3396-3FD7-4E55-AF80-339732D84D49Q29417113-AF830CC2-1060-4A75-B6C2-9F3AC0388497Q33199822-103FE118-A118-4D44-82B1-76ACDE9FB3C1Q33980963-F3EEB286-359D-46B2-BABE-534A2FC7314DQ34296276-022E882E-2292-40B7-BB25-06B824EAAD66Q34538514-F9A701EB-0E33-4C3B-8BF0-0EAF99E1D87EQ35438948-1213A57A-DF50-4615-935C-A764270AC9DCQ35598120-DD18E601-EFAF-4E78-86B4-C28AF8650943Q35851043-42AA6B8E-3B85-472E-B75F-E83078E93F2FQ37504092-050A7243-6B3C-4D7A-A90C-50C601BFDD37Q40432273-FE827298-751B-4434-BE52-4A1E35CB9401Q40496274-A91EB9D3-5832-41AC-B4C1-C74FE1E2EEBFQ40539996-C499B769-9956-407E-A252-CEF32F9BD95BQ40937852-02831C28-3446-4F81-B73A-5DE428BBDCCAQ41108998-B66DC08E-8F53-40A9-984F-F63E58D203F7Q41741892-A79FA921-537C-47D3-A0D2-11B8315A7BDBQ41925341-7D8CA327-10BB-499F-8EED-075363B66D8BQ42981580-91C1C3C2-AD8A-479C-940D-F61575140AA9Q42982733-BBB973D2-31C6-41C7-9BF9-4210B95DE9E5Q42983598-C4C97DA6-4729-41A2-A1D0-96CBA8AD2FBAQ42984088-36474FB7-C2D7-46C8-8E4A-8E9721CFD052Q42987744-69B796DE-DBB4-43FE-B43D-3632C97FB981Q42988588-9CF593E9-D6A7-4D10-97CB-D0CF428989A2Q42989119-4E642250-D234-4727-8014-937A7809BAC7Q42998790-AE3B2AB8-285F-4471-9AB4-DC348019AE44Q43034463-EAEFBC1F-506A-463B-A4B6-58C7CC8E7FA1Q43039139-7A0D8F4E-A04A-4283-8618-D2A3B556853FQ43039277-FCF022F5-5DCA-4F4D-946B-CEEA023CCB05Q43040410-2CB60BB8-C99F-4C17-BA03-DC3E8D7FC6FCQ43047523-D9DC3242-2BA5-4926-AFCE-5FC3FFCC1BF2Q43753038-C9C9ACFF-8F22-4CCB-9A9F-FD08B56A2919Q44703198-2EED68A3-2ACD-43BB-8840-5D358170A753Q44775951-B7BC25FC-72C4-4252-83C3-E54B1C56D120Q44815654-F492599D-DF48-4E94-BBF5-731435E82B04Q44849257-A87A2B56-6C45-4F7F-A951-55EEBE55E686Q45352065-BA0E9AFB-749F-4257-BDF1-FDAC841A034DQ45354052-C4E04C6A-94C1-4925-89D2-7AA4D46C15CBQ45364849-86F54476-F4A3-4B39-83D8-BA678BB61FA0
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Bertrand Nalpas
@ast
Bertrand Nalpas
@en
Bertrand Nalpas
@es
Bertrand Nalpas
@nl
Bertrand Nalpas
@sl
type
label
Bertrand Nalpas
@ast
Bertrand Nalpas
@en
Bertrand Nalpas
@es
Bertrand Nalpas
@nl
Bertrand Nalpas
@sl
prefLabel
Bertrand Nalpas
@ast
Bertrand Nalpas
@en
Bertrand Nalpas
@es
Bertrand Nalpas
@nl
Bertrand Nalpas
@sl
P106
P1153
7006318131
P21
P31
P496
0000-0002-8215-2942